March MIMS update

Some of the recent changes to the medicines landscape, with new products, presentations, indications and contraindications New Products Belantamab mafodotin (rch) (Blenrep) is a humanised immunoglobulin G1 kappa monoclonal antibody conjugated with a cytotoxic agent, maleimidocaproyl monomethyl auristatin F (mcMMAF). Belantamab mafodotin binds to cell surface B cell maturation antigen and is rapidly internalised. Once